Abstract:Abstract Background: Genome-informed and genome-targeted precision treatment for breast cancer have achieved remarkable progress in improving clinical outcomes for patients with specific genetic alterations. However, treatment efficacy is compromised by the current practice of basing treatment decision-making solely on single driver alterations, without considering the role of genetic interactions. Consequently, it is of great necessity to conduct systematic investigations to determine the clinical relevance of genetic interactions. Methods: We established a large-scale multi-omics cohort (N=873) and a real-world clinical sequencing cohort (N=4,421) representing the Asian breast cancer population. Detailed treatment records were collected. We then investigated the prognostic and predictive effects of genetic interactions based on multivariate Cox proportional hazards model and logistic regression model. To validate our findings, we utilized patient-derived organoids and tumor fragments to confirm the associations observed between genetic interactions and drug response. Results: Through integrated analysis of genomics, transcriptomics, proteomics, and metabolomics, we constructed a network comprising 54 co-occurring events and 38 mutually exclusive events, elucidating their association with dysregulated biological processes. External validations were performed in TCGA-BRCA, MSK-IMPACT, METABRIC, and AACR-GENIE datasets, respectively. Furthermore, we systematically revealed the prognostic effects of genetic interactions across distinct clinical subtypes. In triple-negative breast cancer, we found that the co-occurrence of PIK3CAmut-FOXA1mut was associated with unfavorable distant metastasis-free survival while TP53mut-MYBamp and TP53mut-CCNE1amp were associated with decreased overall survival. Additionally, we characterized the genetic interactions that impact the clinical outcomes of patients undergoing specific treatments in the neoadjuvant, adjuvant, and advanced settings. Notably, we identified associations such as TP53mut-AURKAamp with tamoxifen resistance, ERBB2amp-PAK1amp with resistance to trastuzumab-pertuzumab combinations, germline BRCA1mut-MYCamp with sensitivity to PARP1 inhibitors, and TP53mut-MYBamp with immunotherapy resistance. Conclusion: Overall, the consideration of genetic interactions may enhance our understanding of the heterogeneity in treatment response and complement ongoing efforts in precision oncology. Our study suggests that decision-making regarding genome-informed and genome-targeted treatment should extend beyond the scope of single driver alterations. Citation Format: Caijin Lin, Xi Jin, Ding Ma, Chao Chen, Xin Hu, Yi-Zhou Jiang, Zhi-Ming Shao. Comprehensive characterization of genetic interactions in breast cancer reveals therapeutic vulnerabilities [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-02.

The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.

Abstract 1304: Multiomic approaches to illuminate molecular drivers of breast cancer metastasis to the liver

Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis

Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis

Multiomics insights on the onset, progression, and metastatic evolution of breast cancer

Multiomics in Primary and Metastatic Breast Tumors from the AURORA US Network Finds Microenvironment and Epigenetic Drivers of Metastasis

Tumor Biology and Multidisciplinary Strategies of Oligometastasis in Gastrointestinal Cancers

The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches

‘Omics Approaches to Explore the Breast Cancer Landscape

Abstract PO1-15-02: Comprehensive Characterization of Genetic Interactions in Breast Cancer Reveals Therapeutic Vulnerabilities

A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes

Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets

The Landscape of Targeted Therapies in TNBC

Exploring the molecular mechanisms network of breast cancer by multi‐omics analysis

Applying Multi-Omics Toward Tumor Microbiome Research

A Multiomics, Molecular Atlas of Breast Cancer Survivors

Therapeutics targeting the metastatic breast cancer bone microenvironment